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Abstract
Objective This study aims to investigate whether orexi-
genic antipsychotic drugs may induce dyslipidemia and
glucose disturbances in female rats through direct pertur-
bation of metabolically active peripheral tissues, indepen-
dent of prior weight gain.
Methods In the current study, we examined whether a
single intraperitoneal injection of clozapine or olanzapine
induced metabolic disturbances in adult female outbred
Sprague–Dawley rats. Serum glucose and lipid parameters
were measured during time-course experiments up to 48 h.
Real-time quantitative PCR was used to measure specific
transcriptional alterations in lipid and carbohydrate metab-
olism in adipose tissue depots or in the liver.
Results Our results demonstrated that acute administration
of clozapine or olanzapine induced a rapid, robust elevation
of free fatty acids and glucose in serum, followed by
hepatic accumulation of lipids evident after 12–24 h. These
metabolic disturbances were associated with biphasic
patterns of gluconeogenic and lipid-related gene expression
in the liver and in white adipose tissue depots.
Conclusion Our results support that clozapine and
olanzapine are associated with primary effects on
carbohydrate and lipid metabolism associated with
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Introduction
Treatmentwith the atypical antipsychotic drugs clozapine and
olanzapine is associated with elevated risk of weight gain and
other metabolic disturbances (Allison et al. 1999; Leucht et
al. 2009; Lieberman et al. 2005;R u m m e l - K l u g ee ta l .2010).
Among the mechanisms assumed to underlie these adverse
effects are increased appetite and excess food intake,
possibly mediated via histamine H1 and serotonin 5HT2C
receptor antagonism in the hypothalamus (Kroeze et al.
2003; Nasrallah 2008) as well as alterations in hypothalamic
fatty acid metabolism and neuropeptide expression (Ferno et
al. 2011; Kim et al. 2007b; Reynolds and Kirk 2010).
Altered brown adipose tissue thermogenesis has also been
suggested to contribute to antipsychotic-induced weight gain
(Ota et al. 2002;S t e f a n i d i se ta l .2009). However, recent
findings indicate that some antipsychotic-induced metabolic
adverse effects, such as dyslipidemia and glucose dysregu-
lation, may occur independently of weight gain (Albaugh et
al. 2011; Birkenaes et al. 2008;N a g a m i n e2008;N e w c o m e r
2005; Procyshyn et al. 2007; Sacher et al. 2008; Tulipano et
al. 2007). We have previously demonstrated that at the
transcriptional level, several antipsychotic drugs upregulate
lipogenesis controlled by the sterol regulatory element-
binding protein (SREBP) transcription factors in cultured
glial and liver cells (Ferno et al. 2005, 2006). This effect was
proposed as a potentially relevant mechanism for drug-
induced metabolic adverse effects (Ferno et al. 2005; Raeder
et al. 2006) and has been replicated by others in adipocytes
(Yang et al. 2007). The SREBP transcription factor exists as
two isoforms: SREBP1 mainly controls the expression of
fatty acid biosynthesis genes, whereas SREBP2 generally
regulates genes involved in cholesterol biosynthesis and
uptake (for review, see Shimano 2009).
To explore whether atypical antipsychotic drugs exert
direct acute effects on metabolic processes, independent of
weight gain, we recently investigated the effect of a single
intraperitoneal injection of clozapine on hepatic gene
expression and lipid levels in female Sprague–Dawley rats
(Ferno et al. 2009). Clozapine administration rapidly
induced hepatic upregulation of several SREBP-, PPAR-
and LXR-controlled genes as well as hepatic accumulation
of triglycerides, phospholipids, and cholesterol, within
48 h. Our results implied that administration of clozapine
induces direct transcriptional effects in the liver, potentially
facilitating hepatic lipid deposition, independent of food
intake and weight gain. Alternatively, the accumulation of
lipids in liver may indicate that clozapine exerts a direct
effect on white adipose tissue (WAT). It is well-known that
WAT is an important metabolic organ, not only in terms of
lipid storage but also due to its endocrine role, as a source
of hormones and cytokines essential to the regulation of
metabolic homeostasis. We have recently proposed that
initial defects in WAT expandability and/or function may
trigger ectopic fat deposition in other metabolically relevant
organs (Virtue and Vidal-Puig 2008, 2010). Thus, in the
present study, we investigated the acute effects of clozapine
and olanzapine on gene expression in WAT depots and in
the liver in rat, as well as their effects on serum levels of
glucose, lipids, and metabolically active hormones.
Material and methods
Animal studies
Adult female outbred Sprague–Dawley rats (Mollegaard,
Denmark) with body weight from 260 to 275 g were
housed three per cage. The light phase lasted from 0800 to
2000 hours, and ambient temperature was 22–24°C. Before
drug exposure, food was limited to 15 g/day on average,
through which the rats gained weight without developing
obesity, and there was free access to water. The experiments
were carried out in accordance with the Declaration of
Helsinki and the guidelines of the Norwegian Committee
for Experiments on Animals. The number of rats was the
minimum necessary to obtain significant results and in
agreement with the triple R spirit for reduction of the
number of animals used. All procedures were performed so
that suffering of the animals was minimized. We carried out
two separate acute time-course experiments on two differ-
ent occasions, with rats exposed to a single i.p. injection of
either clozapine (25 mg/kg; Sigma, USA) or olanzapine
(5 mg/kg; Toronto Research Chemicals, Canada), dissolved
in 0.5 ml lactic acid (6 μg/ml), adjusted to pH=5.5. Control
animals were injected with corresponding amounts of lactic
acid adjusted to body weight. In relative terms, the dose of
olanzapine was rather low as compared to the high dose of
clozapine. We anticipated that this situation would decrease
the size effect of olanzapine outcome parameters as
compared to clozapine. In order to obtain enough statistical
power, the number of animals exposed to olanzapine (n=9)
was therefore larger than those exposed to clozapine (n=5).
Following the i.p. injections, food was available ad libitum.
In the clozapine experiment, treated and control rats were
killed after 0.25, 0.5, 1, 3, 6, 12, 24, or 48 h. In the
olanzapine experiment, both treated and control rats were
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killed between 0900 and 1200 hours, except for the 6-
h time point where the animals were killed at 1400 hours.
Biological replicate studies were carried out at selected time
points for both clozapine (0.25, 0.5, 12, and 24 h) and
olanzapine (3 and 6 h), with n=5 animals for each time
point. Similar to the first experiment, food was available ad
libitum after injection, and all rats were anesthetized one by
one by isoflurane gas (Isoba vet; Schering-Plough, Den-
mark) and decapitated, and truncal blood was collected.
Samples were taken from the liver median lobe and from
mesenteric, ovarian, and retroperitoneal adipose tissues and
freeze-clamped in liquid nitrogen before storage at −80°C.
Measurements of clozapine and olanzapine serum
concentrations
Determination of serum clozapine and olanzapine levels was
performed with an LC-MS/MS instrument (clozapine)
(Waters, USA), or a UPLC-MS/MS instrument (Waters,
USA), as previously described for clozapine (Ferno et al.
2009), using promazine (Sigma Aldrich, USA) as an internal
standard. The lower quantification threshold of clozapine
and olanzapine was 0.5 and 0.10 nM, respectively.
Hepatic triglyceride, cholesterol, phospholipid,
and glycogen measurements
Levels of glucose, triglycerides, phospholipids, and choles-
terol in the rat liver were measured enzymatically on the
Hitachi 917 system (Roche Diagnostics, Germany) using the
Gluco-quant glucose kit (Roche Diagnostics, Germany), the
GPO-PAP triglyceride kit (Roche Diagnostics, Germany), the
CHOD-PAP cholesterol kit (Roche Diagnostics, Germany),
and the PAP 150 phospholipid kit (Diasys Diagnostics
System, Germany), respectively, according to the manufac-
turers’ instructions. Liver lipids were extracted by the method
ofBligh& Dyer(Blighand Dyer1959), evaporated under N2
and re-dissolved in isopropanol before analysis. Hepatic
glycogen measurements were carried out using a colometric
assay kit (cat. no. K-646-110, BioVision, USA), with
standard curves as recommended by the manufacturer. Ten
milligrams of liver tissue was homogenized in 200 μl
distilled H2O. Ten-microliter homogenate was then diluted
1:10, and measurements were carried out on 5-μld i l u t e d
homogenate.
Leptin, adiponectin, insulin, and glucagon measurements
Truncalveinbloodwascollectedinserumtubes,leftonicefor
30 min and centrifuged at 3,000 rpm for 10 min. Serum was
transferred to pre-cooled Eppendorf tubes immediately after
centrifugation and stored at −20°C. Serum insulin levels were
measured. Serum leptin, adiponectin, insulin, and glucagon
levels were all assessed by means of double-antibody radio-
immunoassays provided by Linco Research (Linco Research,
USA) (Caminos et al. 2005). All samples were assayed in
duplicate within one assay, and the results were expressed in
terms of the leptin, adiponectin, insulin, or glucagon stand-
ards. For leptin, the limit of assay sensitivity was 0.5 ng/ml
with intra- and inter-assay variations at 2.0% and 5.7%,
respectively. For adiponectin, the limit of assay sensitivity
was 1 ng/ml, and the intra- and inter-assay variations were
4.1% and 6.6%, respectively. For insulin, the limit of assay
sensitivity was 0.1 ng/ml, and the intra- and inter-assay
variations were 1.4% and 9.1%, respectively. For glucagon,
the limit of assay sensitivity was 20 pg/ml, and the intra- and
inter-assay variations were 4.9% and 11.7%, respectively.
RNA extraction, cDNA synthesis, and gene expression
analysis
Tissue was homogenized by adding pieces of liver or fat
(about 20 and 100 mg each, respectively) to round-
bottomed 2-ml Eppendorf tubes with 5-mm stainless steel
beads (Qiagen, cat no 69989) and 600 μlR N Al y s i s
buffer (Applied Biosystems, USA). Homogenization was
carried out using a Beadmill TissueLyser (Qiagen). RNA
extraction was performed on the ABI Prism™ 6100
Nucleic Acid PrepStation (Applied Biosystems) for the
liver samples and the RNeasy Lipid Tissue Mini Kit
(Qiagen) for the adipose tissues. Quantity and quality of
the RNA were measured on the NanoDrop® ND-1000
spectrophotometer (NanoDrop Technologies, USA). Real-
time PCR was carried out on an ABI Prism 7900HT
sequence detector system (Applied Biosystems) using
cDNA synthesized by the TaqMan Reverse Transcription
reagents (Applied Biosystems) as template. Each sample
was run in triplicate as previously described (Ferno et al.
2005). Relative gene expression levels were determined by
the comparative Ct method (Winer et al. 1999). Expression
levels were normalized relative to three endogenous
controls, acidic ribosomal phosphoprotein (Arbp/P0), β-
actin (Actb), and glyceraldehyde-3-phosphate dehydroge-
nase (Gapdh), with similar results. Mean fold change
(drug vs. vehicle) was calculated at all time points in the
experiment.
Statistical analysis
Statistical significance was determined by the unpaired
Student’s t test. The p values for the differences in
normalized expression levels between antipsychotic- and
vehicle-treated animals were calculated at all time points.
All statistical tests were conducted with Excel 2003
(Microsoft Corporation, USA).
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Clozapine and olanzapine serum concentrations peak
within the first hour post-intraperitoneal administration
Serum drug concentrations were measured at several time
points in female rats exposed to a single intraperitoneal dose
of clozapine (25 mg/kg) or olanzapine (5 mg/kg) in two
separate time-course experiments, up to 48 and 24 h,
respectively. The serum level (mean ± SD) of clozapine
peaked at 15 min (4.4±0.3 μM), the first measured time point
after the injection, and remained high at 1 h (3.7±0.2 μM)
(Ferno et al. 2009). For olanzapine, the highest serum level
was observed after 1 h (1.3±0.5 μM), which was the first
time point in this experiment (Table 1). In agreement with
the short half-life of antipsychotic drugs in rats, the initial
peak levels were followed by a rapid decline for both drugs,
and serum concentrations of clozapine (Ferno et al. 2009)
and olanzapine (Table 1) were close to zero after 12 h.
Clozapine and olanzapine acutely increase serum lipid
levels and induce hepatic lipid accumulation
To investigate whether clozapine and olanzapine could have
direct effects on lipid-related parameters in serum, inde-
pendent of weight gain, we measured free fatty acids,
triglycerides, total cholesterol, high-density lipoprotein
(HDL) cholesterol, low-density lipoprotein (LDL) choles-
terol, phospholipids, leptin, and adiponectin after a single
dose of the antipsychotic drugs. The most pronounced
change was a rapid and persistent elevation of serum free
fatty acids, evident as early as 15 min after clozapine
injection, peaking (322±50%; mean ± SD, P<0.001) after
30 min (Fig. 1a). Olanzapine also induced a peak level (205
±74%, P<0.01) of free fatty acids within 1 h of its
administration (Fig. 1b). Independent biological experi-
ments confirmed the early increase in free fatty acids for
both drugs (Supplementary Table 1).
Similarly, a moderate, but statistically significant in-
crease in serum triglycerides was observed at 1 h for both
clozapine (151±34%, P<0.05) and olanzapine (140±34%,
P<0.05) relative to vehicle-treated rats, followed by a trend
toward reduced levels at later time points (Table 2). With
respect to total, HDL, and LDL cholesterol, there was a
statistically significant reduction or trend toward reduced
cholesterol levels during the first 3 h for both clozapine and
olanzapine, followed by gradual return to the levels
observed in vehicle-treated rats (Table 2). A similar
tendency was observed for phospholipids (Table 2). To
check for possible gender-specific effects, male Sprague–
Dawley rats were included in the clozapine study (3 h only)
(see separate column in Table 2). With the exception of
triglyceride levels, changes in serum lipids corresponded
well in male and female rats and were particularly evident
for free fatty acids (Table 2). We found that changes in lipid
parameters were only associated with minor, non-
significant changes in serum levels of leptin and adiponec-
tin in clozapine-exposed rats (Table 2). Since the magnitude
of changes in the other serum parameters was most
pronounced for clozapine, leptin, and adiponectin levels,
these were not further investigated in olanzapine-exposed
rats. Similar to what we previously observed for clozapine
(Ferno et al. 2009), olanzapine induced a statistically
significant accumulation of lipids in the liver at the later
time points, most pronounced for triglycerides at 12 h
(Supplementary Table 2).
Antipsychotic-induced changes in carbohydrate metabolism
In addition to their effects on lipid metabolism, antipsy-
chotic agents are associated with increased risk of carbo-
hydrate dysregulation in patients. In our study, single doses
of both clozapine and olanzapine induced rapid and marked
transient elevation of serum glucose levels, with maximum
increase after 30 min (197±29%, P<0.001) for clozapine
and after 1 h (115±9%, P<0.001) for olanzapine (Fig. 2a,
b). The rapidly increased glucose levels were replicated in
an independent biological experiment with clozapine
(Supplementary Table 1). Glucagon and insulin are key
regulators of carbohydrate homeostasis, with opposite
effects on glucose metabolism. Interestingly, the
clozapine-induced increase in glucose levels was associated
with elevated serum glucagon levels in two independent
experiments, whereas the effect on serum insulin levels was
inconsistent (Table 2 and Supplementary Table 1), as could
be anticipated from the non-standardized nutritional status.
The relatively low dose of olanzapine did not induce any
statistically significant effects on either serum insulin or
glucagon levels (Table 2).
Based on the increased serum glucose and glucagon
levels, we investigated transcriptional changes of key
Table 1 Olanzapine serum concentrations after single injection in
female SD rats
Time Concentration (nM)
1 h 1,333±448
3 h 536±119
6 h 149±59
12 h 5±3
24 h 0.5±0.4
Olanzapine serum concentration (nanomolars; mean ± SD) measured
after a single intraperitoneal injection (5 mg/kg). Measurements were
done at 1, 3, 6, 12, and 24 h after the olanzapine injection. The data
are representative of n=9 animals
786 Psychopharmacology (2012) 219:783–794gluconeogenic genes in the liver. In clozapine-exposed rats,
phosphoenolpyruvate carboxykinase (Pepck) was upregu-
lated in parallel with peaking drug concentrations at early
time points, with a maximum expression level after 1 h
(2.69±0.30, P<0.01). The early upregulation was followed
by a non-significant trend toward downregulation at later
time points, as serum drug levels declined (Fig. 3a).
Another important modulator of gluconeogenesis in the
liver, the peroxisome proliferator-activated receptor gamma
coactivator 1 alpha (Pgc1a), also displayed maximum
Fig. 1 The effect of clozapine and olanzapine on serum free fatty acid
(FFA) levels. The serum levels of FFAs were measured in rats exposed
to a clozapine (25 m/kg; dark bars) or vehicle (lactic acid; 6 μg/ml;
light bars)o rb olanzapine (5 m/kg; dark bars) or vehicle (lactic acid;
6 μg/ml; light bars). The levels were measured at 0.25, 0.5, 1, 3, 6,
12, 24, and 48 h in the clozapine experiment (n=5) and at 1, 3, 6, 12,
and 24 h in the olanzapine experiment (n=9). **p<0.01; ***p<0.001
Table 2 Serum levels of metabolic parameters following clozapine and olanzapine exposure to rats
15 min 30 min 1 h 3 h 3 h (male) 6 h 12 h 24 h 48 h
Clozapine
TG 94±16 123±20 151±34* 127±12 82±20 73±14 82±26 102±15 102±27
Total cholesterol 79±5* 85±10 75±10 85±07 83±12* 95±18 111±7 99±9 102±26
HDL cholesterol 82±6 88±9 80±8* 89±9 90±12 104±19 105±7 90±6 104±27
LDL cholesterol 120±25 104±8 89±17 89±13 80±33 106±26 155±35* 103±24 108±38
PL 81±9 88±12 75±14 91±7 87±7* 98±15 114±12 112±10 104±16
FFA F F F F 3.60±0.79*** F F F F
Adiponectin – 78±25 – 98±30 –– 79±27 87±31 81±14
Leptin 62±47 88±53 96±27 163±42 103±39 158±40 94±32 67±12 69±14
Glucagon 128±102 130±24* – 110±15 – 76±15 –– –
Insulin 11±8*** 66±40 47±38 44±14 38±23* 43±21* 67±27 56±18 51±39
Olanzapine
TG 140±34** 110±36 84±8 71±25 84±22
Total cholesterol 97±17 85±9* 97±12 100±19 100±11
HDL cholesterol 97±17 87±10 99±12 102±17 101±10
LDL cholesterol 102±27 70±14* 97±20 87±22 104±21
PL 96±12 88±9* 96±9 100±18 97±9
Glucagon 114±28 131±122 –– –
Insulin 121±42 106±46 98±32 121±48 113±50
The serum levels (mean ± SEM) of metabolic parameters during time-course experiments measured in rats exposed to clozapine (25 mg/kg) at
0.25, 0.5, 1, 3, 6, 12, 24, and 48 h (n=5). The levels of TG, total cholesterol, HDL cholesterol, LDL cholesterol and PL, FFAs, and insulin were
measured at all time points for both treatment, whereas glucagon was measured only at selected time points. Adiponectin and leptin were
measured in the clozapine-exposed rats only. The levels are given relative to vehicle-exposed rats that were defined as 100%
TG triglycerides, HDL high-density lipoprotein, LDL low-density lipoprotein, PL phospholipids, FFAs free fatty acids, F data available in Fig. 1a
*p<0.05; **p<0.01; ***p<0.001
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clozapine-exposed rats (Fig. 3b). We also measured the
expression levels of hepatic insulin receptor substrate 2
(Irs2), an essential component of the insulin-signaling
pathway in liver typically downregulated in steatosis-
associated hepatic insulin resistance (Shimomura et al.
2000). A striking upregulation of Irs2 was evident after
30 min (6.51±0.87, P<0.01) in clozapine-exposed rats,
with subsequent downregulation to the level in rats exposed
to vehicle (Fig. 3c). A comparable, but less pronounced,
transcriptional pattern was observed in olanzapine-exposed
rats for all the abovementioned genes (Fig. 3d–f). In WAT,
the expression of the insulin-responsive glucose transporter
4( Glut4) was markedly reduced by both clozapine and
olanzapine at the later time points in all adipose tissue
depots (Table 3 and Supplementary Tables 3, 4, and 5).
Glycogen breakdown in the liver is another mecha-
nism that could potentially contribute to the observed
increase in serum glucose levels. Hepatic glycogen levels
were not significantly altered at the early time points
(data not shown), but a significant reduction was
observed at 24 h for both clozapine (50±11%, P<0.05)
and olanzapine (56±6%, P<0.05), relative to vehicle-
treated rats. Hepatic expression levels of glycogen phos-
phorylase (Pygl), encoding the rate-limiting enzyme of
glycogen catabolism in the liver, were examined in
clozapine-treated animals, but no significant changes were
found at any time point (data not shown).
Clozapine and olanzapine induce transcriptional changes
of lipid-related genes in liver and in WAT depots
The marked elevation of serum free fatty acids and the
accumulation of hepatic lipids observed after a single dose
of clozapine or olanzapine were accompanied by immediate
drug-induced transcriptional activation of Srebp-controlled
lipogenic genes in the liver for both clozapine (Ferno et al.
2009) and olanzapine (Supplementary Table 6). The initial
upregulation was followed by downregulation at later time
points, corresponding with rapidly declining serum drug
concentrations. For clozapine, such biphasic patterns of
Srebp-controlled gene expression were also observed in the
WAT depots (mesenteric fat, ovarian fat, and retroperitoneal
fat), with most pronounced effects in mesenteric WAT.
Analogous to the situation in liver, the mesenteric WAT
displayed rapid upregulation for genes involved in fatty
acid biosynthesis (e.g., Srebp1c and Fasn, an Srebp1 target
gene) and adipogenesis (e.g., Pparg) and for Srebp2 target
genes involved in cholesterol biosynthesis (e.g., Hmgcr)
(Fig. 4 and Table 3). Similar effects were observed in
ovarian WAT (Supplementary Table 3), whereas the initial
effect in retroperitoneal WAT was opposite, with a trend
toward downregulation at the early time points (Supple-
mentary Table 4). In mesenteric WAT from olanzapine-
exposed rats, we observed no statistically significant
upregulation of lipid-related genes, although a statistically
significant downregulation was observed for Pparg after 3
and 6 h (Supplementary Table 5). As an indication of drug-
induced increase of lipogenesis at early time points, hepatic
expression of the cholesterol esterification gene Soat1 was
highly upregulated, both by clozapine (Ferno et al. 2009)
and by olanzapine (Supplementary Table 6). Clozapine also
induced a consistent, rapid upregulation of Soat1 in all WAT
depots (Table 3 and Supplementary Table 3 and 4). A
comparable effect on Soat1 was induced by olanzapine in
mesenteric WAT (Supplementary Table 5).
Immediate drug-induced effects on lipolytic activity in
adipose tissues could be of relevance for the elevated serum
lipid levels. We therefore measured the expression levels of
several lipase-encoding genes, including hormone-sensitive
Fig. 2 The effect of clozapine and olanzapine on serum glucose level.
The serum levels of glucose were measured in rats exposed to a
clozapine (25 m/kg; dark bars) or vehicle (lactic acid; 6 μg/ml; light
bars)o rb olanzapine (5 m/kg; dark bars) or vehicle (lactic acid; 6 μg/
ml; light bars). The levels were measured at 0.25, 0.5, 1, 3, 6, 12, 24,
and 48 h in the clozapine experiment (n=5) and at 1, 3, 6, 12, and
24 h in the olanzapine experiment (n=9). **p<0.01; ***p<0.001
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triglyceride lipase (Atgl; Pnpla2) in all three WAT depots.
Indeed, in mesenteric WAT from clozapine-exposed rats, we
found statistically significant upregulation of Hsl (1.43±
0.12, P=0.04) at 3 h, followed by downregulation at later
time points (Table 3). Similar patterns were observed for
Lpl and Atgl, although the initial upregulation did not reach
statistical significance (Table 3). A biphasic pattern equiv-
alent to that observed for lipogenic genes was also found in
ovarian WAT from clozapine-exposed rats (Supplementary
Table 3), whereas in retroperitoneal WAT we observed an
opposite immediate effect for all measured lipase genes,
with downregulation at early time points (Supplementary
Table 4). Olanzapine did not affect the expression levels of
any of the investigated lipase genes in mesenteric WAT
(Supplementary Table 5). Taken together, these results
indicated that the drug-induced initial effects on lipid-
related gene expression were comparable across various
metabolically active tissues, whereas the transcriptional
changes at the later time points, occurring in parallel with
declining drug serum concentrations, were less uniform.
The late phase transcriptional downregulation—a rebound
effect
The initial upregulation observed for several genes in this
study paralleled the serum drug concentration peaks and was
evident across several metabolically active tissues, but most
pronounced in the liver both for clozapine (Ferno et al. 2009)
and for olanzapine (Supplementary Table 6). The subsequent
downregulation corresponded with declining serum drug
concentrations, with the degree of downregulation varying
across different tissues and for the different genes within
each tissue. To investigate whether the downregulation was a
delayed direct effect of the drugs, or alternatively, a
compensatory feedback mechanism in response to the early
upregulation, we explored whether clozapine could also
stimulate transcriptional activation in the late phase of
transcriptional downregulation. A second injection of cloza-
pine (25 mg/kg) was therefore administered 11 h after the
first dose and the rats were killed 1 h later, i.e., 12 h after the
initial injection. We found that the expression levels of Fasn,
Soat1, Pepck,a n dIrs2, all of which displayed high initial
Fig. 3 The effect of clozapine and olanzapine on genes involved in
gluconeogenesis and insulin signaling. Relative gene expression of a
Pepck, b Pgc1a, and c Irs2 in the liver from rats exposed to clozapine
(25 m/kg) and d Pepck, e Pgc1a, and f Irs2 in the liver from rats
exposed to olanzapine (5 mg/kg), measured as fold change (mean ±
SEM) relative to vehicle-exposed rats. The expression levels were
normalized relative to the expression of the ribosomal gene P0. The
relative levels were measured at 0.25, 0.5, 1, 3, 6, 12, 24, and 48 h in
the clozapine experiment (n=5) and at 1, 3, 6, 12, and 24 h in the
olanzapine experiment (n=9). *p<0.05; **p<0.01; ***p<0.001
Psychopharmacology (2012) 219:783–794 789fold change, were significantly upregulated or demonstrated
a trend toward upregulation 1 h after the second dose of
clozapine administered during the rebound phase, although
to a lesser extent than by the first dose (Fig. 5).
Fig. 4 The effect of clozapineon
lipogenic genes in mesenteric
WAT. Relative gene expression in
mesenteric fat of a Srebp1c, b
Fasn, c Srebp2,a n dd Hmgcr,
measured as fold change (mean ±
SEM) in clozapine- (25 m/kg)
relative to vehicle-exposed rats.
The expression levels were nor-
malized relative to the expression
of the ribosomal gene P0. The
relative levels were measured at
0 . 2 5 ,0 . 5 ,1 ,3 ,6 ,1 2 ,2 4 ,a n d
48 h, with each data point repre-
sentative of n=5 animals. *p<
0.05; **p<0.01
Table 3 The effect of clozapine on lipogenesis-related gene expression in mesenteric WAT
15 min 30 min 1 h 3 h 6 h 12 h 24 h 48 h
Fabp4 0.99±0.07 0.98±0.19 1.55±0.12* 1.08±0.11 1.26±0.18 0.60±0.11 0.47±0.07** 0.96±0.21
Pparg 1.28±0.08 1.19±0.13 1.76±0.22* 1.03±0.11 0.51±0.09 0.90±0.25 0.76±0.07* 0.83±0.19
Dgat1 1.03±0.07 1.28±0.16 1.49±0.13 1.39±0.14 2.23±0.30* 0.50±0.08* 0.65±0.09* 1.04±0.24
Dgat2 1.34±0.27 1.23±0.16 1.78±0.23 1.03±0.12 0.92±0.17 0.34±0.05* 0.44±0.06** 0.64±0.17
Gpam 1.34±0.34 0.99±0.08 0.86±0.20 1.21±0.25 1.36±0.43 0.28±0.02 0.28±0.06* 0.50±0.16
Hmgcs1 1.52±0.39 1.22±0.15 1.16±0.22 0.75±0.20 0.93±0.18 0.70±0.09 0.57±0.11* 1.01±0.17
Ldlr 1.76±0.20* 0.91±0.27 1.95±0.17** 2.49±0.54 2.09±0.35* 1.20±0.14 0.97±0.17 0.91±0.24
Abca1 1.01±0.13 0.70±0.19 1.25±0.06 1.33±0.31 1.01±0.21 0.70±0.14 1.00±0.15 1.19±0.17
Acox1 1.35±0.26 1.28±0.11 1.58±0.21 1.63±0.22 1.55±0.13 0.61±0.16 0.45±0.03*** 0.77±0.17
Soat 1.03±0.09 1.51±0.18* 2.08±0.27* 1.39±0.13* 1.75±0.31 1.05±0.20 1.57±0.30 1.05±0.09
Pnpla2 1.23±0.08 1.04±0.15 1.19±0.10 1.12±0.06 1.21±0.14 0.71±0.16 0.50±0.10** 1.01±0.25
Lipe 1.66±0.09 1.18±0.16 1.40±0.15 1.43±0.12* 1.48±0.11 0.70±0.10 0.53±0.11** 0.92±0.19
Lpl 0.87±0.08 0.91±0.28 1.54±0.21 1.51±0.19 1.56±0.19 0.80±0.20 0.50±0.04 0.53±0.15
Adipoq 1.00±0.12 1.21±0.15 1.20±0.13 1.24±0.20 1.05±0.08 0.66±0.14 0.40±0.04* 0.93±0.21
Glut4 1.86±0.57 1.06±0.14 0.65±0.18 1.09±0.10 1.72±0.45 0.14±0.02* 0.16±0.05* 0.35±0.11*
Relative expression in mesenteric WAT of several genes involved in lipid homeostasis, measured as fold change (mean ± SEM) in clozapine-
(25 mg/kg) relative to vehicle-exposed rats. Genes involved in adipogenesis (Fabp4 and Pparg), lipid biosynthesis and transport (Dgat1, Dgat2,
Gpam, Hmgcs1, Ldlr, and Abca1), fatty acid β-oxidation (Acox1), cholesterol esterification (Soat1), lipolysis (Pnpla2, Lipe, and Lpl), adipokine
production (Adipoq), and glucose transport (Glut4) were examined. The expression levels were normalized relative to the expression of the
ribosomal gene P0. The relative levels were measured at 0.25, 0.5, 1, 3, 6, 12, 24, and 48 h with each data is representative of n=5 animals for
each gene at each condition at each time point
*p<0.05; **p<0.01; ***p<0.001
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In this study, we demonstrated that administration of a
single dose of clozapine or olanzapine to non-fasted female
rats rapidly increased serum levels of glucose, glucagon,
and free fatty acids and led to accumulation of hepatic
lipids at late time points. These metabolic changes were
associated with a biphasic pattern of lipid-related gene
expression in both liver and WAT depots, generally
displaying a rapid upregulation and, in parallel with
declining drug serum concentrations, a subsequent normal-
ization or downregulation. Genes involved in gluconeogen-
esis also displayed marked initial upregulation, coinciding
with increased levels of serum glucagon but not insulin.
Antipsychotic-induced elevation of serum free fatty acids
and associated lipid-related gene expression
One plausible mechanism for the rapid elevation of serum
free fatty acids is instant, lipase-mediated degradation of
triglycerides in WAT. This is supported by the rapidly
increased expression of lipase genes, such as Hsl, Lpl, and
Atgl, both in mesenteric and ovarian WAT. Although it is
unlikely that rapid effects on metabolic serum parameters
are mediated via transcriptional events, the observed
mRNA changes may reflect initial alterations at the protein
and enzymatic activity level. Instant lipolytic activity in
WAT with subsequent free fatty acid elevation in serum may
involve a stress-like increase in sympathetic nervous
activity and catecholamine release (Bartness and Song
2007; Romijn and Fliers 2005). In this sense, it is well
established that both clozapine and olanzapine block the
antilipolytic α2-adrenoceptors (Langin 2006; Roth et al.
2004).
Clozapine and olanzapine elevate serum glucose
and glucagon and markedly induce hepatic gluconeogenic
gene expression
The rapid increase in serum glucose levels induced by
clozapine and olanzapine and the parallel upregulation of
the gluconeogenic genes Pepck and Pgc1α in the liver are
consistent with recent findings of antipsychotic-induced
hepatic glucose production in rats (Albaugh et al. 2011;
Fig. 5 Transcriptional effects in
liver of subsequent injections
with clozapine. Relative expres-
sion levels of a Soat1, b Fasn, c
Pepck, and d Irs2, following
two subsequent injections, con-
taining either vehicle (lactic ac-
id; 6 μg/ml) or clozapine
(25 mg/kg) in various combina-
tions. The injections were ad-
ministered 12 and 1 h before
killing, in the following combi-
nations: Ctrl (vehicle 12 h/vehi-
cle 1 h), clozapine 1 h (vehicle
12 h/clozapine 1 h), clozapine
12 h (clozapine 12 h/vehicle
1 h), and clozapine 12+1 h
(clozapine 12 h/clozapine 1 h).
The expression levels were nor-
malized relative to the expres-
sion of the ribosomal gene P0.
Each data point representative of
n=5 animals. *p<0.05; **p<
0.01; ***p<0.001
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In our study, these effects coincided with elevated serum
glucagon levels rather than altered insulin levels, in line
with findings of others that increased hepatic glucose
production is mediated through a rise in serum glucagon
levels (Smith et al. 2008; Smith et al. 2009). Glycogenol-
ysis could also potentially contribute to elevated serum
glucose, but in our experiments, hepatic glycogen levels
were unaltered at the early time points, when serum glucose
levels were peaking. Others have proposed that
antipsychotic-induced hepatic glucose production results
from suppressed insulin secretion from β-cells as well as
from reduced hepatic insulin sensitivity (Chintoh et al.
2009). The rapid, marked increase in hepatic Irs2 expres-
sion in our study is suggestive of intact hepatic insulin
signaling at the early time points, indicating that drug-
induced insulin resistance in the liver did not markedly
contribute to the elevated serum glucose. However, it
should be kept in mind that several pathological mecha-
nisms may coincide, and our data do not exclude the
possibility that primary drug-induced disturbances on lipid
homeostasis may reduce hepatic insulin sensitivity beyond
the initial stage. The reduced levels of hepatic glycogen
observed at 24 h are compatible with such a scenario.
Antipsychotic-induced hepatic insulin resistance has been
suggested to be mediated via the hypothalamic–pituitary–
adrenal axis, involving increased corticosteroids levels
(Martins et al. 2010; Tulipano et al. 2007). In line with
this, antipsychotic-induced glucose and corticosteroid
responses have been suggested to be causally related (Assie
et al. 2008). Corticosteroids are known to stimulate
lipolysis in WAT (Duclos et al. 2005; Hauner and Pfeiffer
1989), and drug-induced elevation of corticosteroids may
thus also be relevant for the observed antipsychotic-induced
elevation of free fatty acids in our study.
Biphasic gene expression—direct effects followed
by feedback mechanisms?
The biphasic gene expression pattern, with initial
upregulation and subsequent downregulation, was con-
s i s t e n tb o t hi nl i v e ra n di nW A Td e p o t s .T h i sp a t t e r nw a s
particularly evident in clozapine-treated animals, possibly
related to the relatively high clozapine dose chosen to
challenge the system and to compensate for the rapid
half-life of antipsychotic drugs in rats. The biphasic
expression pattern paralleled serum drug concentrations,
with transcriptional decrease at later time points likely
aggravated by compensatory rebound effects occurring in
response to the initial, drug-induced, non-physiological
activation. A second dose of clozapine, administered
during this rebound phase, induced a blunted but still
robust transcriptional reactivation of genes involved in
both lipid (Soat1 and Fasn) and carbohydrate (Pepck and
Irs2) metabolism, strongly suggesting that the late phase
downregulation is indeed a feedback effect and not a direct
effect of the drugs.
The early upregulation of Srepb-controlled gene
expression confirms our finding from cell cultures of a
direct antipsychotic drug effect on lipogenic gene
expression. The subsequent downregulation of Srebp-
controlled gene expression observed both in liver and in
adipose tissue from clozapine-exposed rats appeared
paradoxical in light of the concomitant hepatic lipid
accumulation. However, in the liver, the reduced tran-
scription may be explained by the abovementioned
feedback mechanisms that are probably, at least in part,
triggered by increased serum lipid load from the
elevated serum free fatty acids. With respect to adipose
tissue, reduced expression of lipogenic/adipogenic genes
may in fact be compatible with hepatic lipid accumula-
tion, since it indicates that WAT storage capacity is
temporarily reduced, which may contribute to elevation
of blood lipids and lipid accumulation in non-adipose
tissues (Frayn 2002; Kim et al. 2007a; Lazar 2005;
Martinez de Morentin et al. 2010; Virtue and Vidal-Puig
2008). Thus, the reduced lipogenic gene expression in
WAT depots at late time points may represent an
additional mechanism contributing to the sustained
elevation of serum free fatty acids and accumulation of
hepatic lipids in rat. The downregulation of the insulin-
responsive Srebp1c and its target genes in WAT at the late
time points suggests a state of reduced insulin sensitivity
(Deng et al. 2007; Ranganathan et al. 2006). This is in
agreement with the concomitant reduction of glycogen
levels in the liver, indicative of hepatic glycogenolysis. A
state of reduced insulin signaling in WATis also supported
by the downregulation of the insulin sensitivity marker
Glut4 (Shepherd and Kahn 1999).
In conclusion, we here demonstrate that acute administra-
tion of clozapine or olanzapine rapidly increases serum free
fatty acids and glucose levels, associated with hepatic lipid
accumulation and immediate, drug-induced transcriptional
activationoflipidhomeostasisgenesinWATdepotsandinthe
liver. The antipsychotic-induced elevation of serum glucose
levels appears to be related to transcriptional activation of
hepatic gluconeogenesis and to changes in serum glucagon
rather than serum insulin levels. Clozapine administration
elicits a more potent metabolic response than olanzapine, but
this is likely attributable to the clozapine dose. The similar
findings in clozapine- and olanzapine-treated rats demonstrate
that these antipsychotic drugs are able to exert direct drug
effects on peripheral metabolically active tissues, independent
of increased food intake and weight gain, and that such effects
may be relevant for the metabolic disturbances associated
with atypical antipsychotic drugs.
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